

30 July 2018

**Deltex Medical Group plc**  
(“Deltex Medical” or the “Group”)

**Director Dealing**

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), was informed on Friday 27 July 2018 that Andy Mears, Chief Executive Officer of the Company, purchased 2,234,222 ordinary shares of 1 pence each in the Company (“Ordinary Shares”) at a price of 0.89 pence per Ordinary Share during the day.

Following this transaction, Mr Mears’ beneficial ownership is 2,781,808 Ordinary Shares, representing approximately 0.6 per cent. of Deltex Medical’s issued ordinary share capital.

**For further information, please contact:-**

**Deltex Medical Group plc**

01243 774 837

[investorinfo@deltexmedical.com](mailto:investorinfo@deltexmedical.com)

Nigel Keen, Chairman  
Andy Mears, Chief Executive  
Jonathan Shaw, Group Finance Director

**Nominated Adviser & Broker**

Arden Partners plc

020 7614 5900

Chris Hardie  
Ciaran Walsh

**Joint Broker**

Turner Pope Investments (TPI) Ltd

0203 621 4120

[info@turnerpope.com](mailto:info@turnerpope.com)

Andy Thacker

**Financial Public Relations**

IFC Advisory

0203 934 6630

Tim Metcalfe  
Graham Herring  
Heather Armstrong

**Notes for Editors**

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical’s proprietary ODM (TrueVue™ Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVue™ Doppler, which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical's TrueVue™ System on the CardioQ-ODM+ monitor platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography (TrueVue™ Impedance) is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis (TrueVue™ Pressurewave) uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

### Group goal

Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform, a 'haemodynamic workstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

[Note: This announcement contains inside information for the purposes of Article 7 of Regulation \(EU\) No 596/2014.](#)

### Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated with them.

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Names	Andy Mears – Chief Executive Officer
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	See 1(a) above for position - classified as a PDMR of Deltex Medical
b)	Initial notification /Amendment	Initial
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	

a)	Name	Deltex Medial Group plc	
b)	LEI	213800XN34P6LI8J6M39	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Ordinary shares of 1 pence each ("Ordinary Shares")	
b)	Identification code	GB0059337583	
c)	Nature of the transaction	Purchase of Ordinary Shares	
d)	Price(s) and volume(s)	Prices(s)	Volume(s)
		0.89 pence	2,234,222
d)	Aggregated information  - Aggregated volume  - Price	N/a	
e)	Date of the transaction	27 July 2018	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	